Pharma major Lupin announced that it has received approval from UK MHRA (United Kingdom's Medicines and Healthcare products Regulatory Agency) for its Goa facility. The unit was inspected by UK MHRA in March 2018 and there were no critical or major observations cited.

Nilesh Gupta, Managing Director, Lupin, said, "The outcome of this inspection is a positive and encouraging sign for us, and is a testament to our commitment to maintain global manufacturing standards and best practices. This approval from UK MHRA is a significant development for our Goa plant."

Shares of the company declined Rs 22.95, or 2.65%, to trade at Rs 842.25. The total volume of shares traded was 505,301 at the BSE (11.09 a.m., Monday).